RNS Number : 3516O
Hikma Pharmaceuticals Plc
02 October 2023


Hikma Pharmaceuticals PLC

(the Company)

Total Voting Rights and Capital


LONDON, 2 October 2023 - In accordance with section 5.6.1 of the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules (the 'Rules'), Hikma Pharmaceuticals PLC
(LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market of the following:


As at 30 September 2023, the issued share capital of the Company comprised of 221,079,173 Ordinary Shares of 10 pence each ('Shares') with voting rights. This figure excludes 12,833,233 Shares held in treasury, which do not have voting rights.


The figure of 221,079,173 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.




- ENDS -




Hikma Pharmaceuticals PLC



Helen Middlemist

Deputy Company Secretary

+44 20 7399 2760



About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.